The British In Vitro Diagnostics Association (BIVDA) has welcomed guidance issued recently by the National Institute for Health and Clinical Excellence (NICE) on the treatment and management of type 2 diabetes. The guidance stresses the importance of self-monitoring of blood glucose levels in managing the disease.
Type 2 diabetes is the most common form of the disease and affects over two million people in the United Kingdom alone. The provision of blood glucose monitoring devices allows these people to manage their condition independently, and BIVDA fully welcomes the new point-of-care initiative.
Commenting on the guidance, BIVDA director general Doris-Ann Williams said: “We welcome the new guidance issued by NICE, which encourages the self-monitoring of blood glucose levels by people with diabetes. It forms a central part of diabetes management and allows individuals to manage their condition independently, with increased freedom and flexibility.”
www.bivda.co.uk